Durable Ibrutinib Responses in Relapsed/Refractory Marginal Zone Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durable Ibrutinib Responses in Relapsed/Refractory Marginal Zone Lymphoma: Long-Term Follow-Up and Biomarker Analysis
Blood Adv 2020 Nov 24;4(22)5773-5784, A Noy, S de Vos, M Coleman, P Martin, CR Flowers, C Thieblemont, F Morschhauser, GP Collins, S Ma, S Peles, SD Smith, JC Barrientos, E Chong, S Wu, LW Cheung, K Kwei, B Hauns, I Arango-Hisijara, R ChenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.